Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A Post author: Post published:September 25, 2023 Post category:uncategorized The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO. You Might Also Like Mid afternoon inhaler use may improve nighttime asthma control April 15, 2025 COVID-19 vaccine associated with reduced risk of cardiac and clot-related complications after SARS-CoV-2 infection March 18, 2024 Inside project 2025: Former Trump official outlines hard right turn against abortion August 6, 2024
COVID-19 vaccine associated with reduced risk of cardiac and clot-related complications after SARS-CoV-2 infection March 18, 2024